Rheumatology Advance Access originally published online on October 14, 2009
Rheumatology 2009 48(12):1619-1620; doi:10.1093/rheumatology/kep322
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability
1Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Italy
Correspondence to: Lorenzo Beretta, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Pace 9, Milan, Italy. E-mail: lorberimm@hotmail.com
| The first 10% of the full text of this article appears below. |
SIR, In the June issue of Rheumatology, Lee and colleagues [1] conducted a pharmacogenomic study on a cohort of RA patients receiving MTX. The authors were concerned about the possibility of spurious, false
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Dervieux Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability: reply Rheumatology, December 1, 2009; 48(12): 1620 - 1620. [Full Text] [PDF] |
||||
